Skip to main content

Table 1 Patient demographics and clinical characteristics

From: Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure

Characteristic

No. of patients

Total

P value

 

CCD = 0 mg/m2

CCD(1-200 mg/m2)

CCD > 200 mg/m2

  
 

708(100%)

2230(100%)

185(100%)

3123(100%)

 

Sex

    

0.417

 Male

518(73.2%)

1663(74.6%)

144(77.8%)

2325(74.4%)

 

 Female

190(26.8%)

567(25.4%)

41(22.2)

798(25.6%)

 

Histology

    

0.550

 WHO Type I-II

22(3.1%)

63(2.8%)

3(1.6%)

87(2.8%)

 

 WHO Type III

687(96.9%)

2168(97.2%)

182(98.4%)

3036(97.2%)

 

Age, year

    

< 0.001

 ≤ 45

319(45.1%)

1246 (55.9%)

129(69.7%)

1694(54.2%)

 

 ××45

389(54.9%)

1040(44.1%)

56(30.3%)

1429(45.7%)

 

Smoking history

    

0.001

 No

463(65.4%)

1352(60.6%)

135(73.0%)

1950(62.4%)

 

 Yes

245(34.6%)

878(39.4%)

50(27.1%)

1173(37.6%)

 

Drinking history

    

0.025

 No

628(88.7%)

1887(84.6%)

160(86.5%)

2675(85.6%)

 

 Yes

80(11.3%)

343(15.4%)

25(13.5%)

448(14.4%)

 

Family history of cancer

   

0.158

 No

535(75.6%)

1644(73.7%)

127(68.6%)

2306(73.8%)

 

 Yes

173(24.4%)

586(26.3%)

58(31.4%)

817(26.2%)

 

T stage *

    

0.461

 T1-2

99(14.0%)

287(12.9%)

29(15.7%)

415(13.3%)

 

 T3-4

609(86.0%)

1943(87.1%)

156(84.3%)

2708(86.7%)

 

N stage *

    

0.007

 N0-1

369(52.1%)

1028(46.1%)

98(53.0%)

1495(47.9%)

 

 N2-3

339(47.9%)

1202(53.9%)

87(47.0%)

1628(52.1%)

 

Overall stage *

    

< 0.001

 III

423(59.7%)

1035 (46.4%)

78(42.2%)

1536(49.1%)

 

 IVa

285(40.3%)

1195(53.6%)

107(57.8%)

1587(50.8%)

 

EBV DNA load, copy/ml

   

0.151

 < 4000

325(45.9%)

932(41.8%)

81(43.8%)

1338(42.8%)

 

 ≥ 4000

383(54.1%)

1298(58.2%)

104(56.2%)

1785(57.2%)

 

 IC cycles

    

< 0.001

 ≤ 2 cycles

465(65.7%)

1226(55.0%)

67(36.2%)

1758(56.3%)

 

 > 2 cycles

243(34.3%)

1004(45.0%)

118(63.8%)

1365(43.7%)

 

ELRF

    

0.950

 No

694(98.0%

2188(98.1%)

182(98.4%)

3064(98.1%)

 

 Yes

14(2.0%)

42(1.9%)

3(1.6%)

59(1.9%)

 

LLRF

    

0.485

 No

621(87.7%)

1987(89.1%)

167(90.3%)

2775(88.9%)

 

 Yes

87(12.3%)

243(10.9%)

18(9.7%)

348(11.1%)

 

EDF

    

0.045

 No

636(89.8%)

2032(91.1%)

177(95.7%)

2845(91.1%)

 

 Yes

72(10.2%)

198(8.9%)

8(4.3%)

278(8.9%)

 

LDF

    

0.700

 No

653(92.2%)

2063(92.5%)

174(94.1%)

2890(92.5%)

 

 Yes

55(7.8%)

167(7.5%)

11(5.9%)

233(7.5%)

 
  1. Abbreviations: ELRF Early locoregional failure, LLRF Late locoregional failure, EDF Early distant failure, LDF Late distant failure, WHO World Health Organization, EBV Epstein–Barr virus, CCD Cumulative cisplatin dose
  2. *According to the 8th edition of the American Joint Commission on Cancer staging system
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us